Compare Huntington Bancshares Incorporated (HBAN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs ResMed Inc. — how do they compare? Huntington Bancshares Incorporated trades at $15.32 (market cap $31.04B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Huntington Bancshares Incorporated and ResMed Inc. are close in size by market cap, and Huntington Bancshares Incorporated pays the higher dividend (4.04%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and ResMed Inc. for 51 Days on average.
| HBAN | RMD | |
|---|---|---|
Market Cap | $31.04B | $31.89B |
Volume | 23,864,172 | 618,314 |
Sector | Financials | Health |
52-Week High | $19.27 | $275.96 |
52-Week Low | $15.02 | $182.82 |
Typical Hold Time | 52 Days | 51 Days |
Enterprise Value | $49.57B | $31.24B |
Dividend Yield | 4.04% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.37, up 1.32% today, but faces a bearish technical outlook with support at $15 and resistance at $16. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026, with Q3 2026 results pending. Revenue grew to $8.13B in 2025, and the stock trades at a P/E of 11.82, below the industry average, while analyst sentiment is split with a consensus price target of $19.60.
HBAN offers value with solid profitability and shareholder returns via dividends and buybacks, but near-term headwinds include interest rate pressures, margin compression, and lowered 2027 guidance. Risks involve economic sensitivity and competitive lending markets, yet institutional interest remains with significant holdings. The stock presents a cautious opportunity for value investors amid volatility.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
